Roles of E-Cadherin (CDH1) Genetic Variations in Cancer Risk: a Meta-analysis

Abstract

E-Cadherin (CDH1) genetic variations may be involved in invasion and metastasis of various cancers by altering gene transcriptional activity of epithelial cells. However, published studies on the association of CDH1 gene polymorphisms and cancer risk remain contradictory, owing to differences in living habits and genetic backgrounds. To derive a more better and comprehensive conclusion, the present meta-analysis was performed including 57 eligible studies of the association between polymorphisms of CDH1 gene promoter -160 C>A, -347 G>GA and 3'-UTR +54 C>T and cancer risk. Results showed that these three polymorphisms of CDH1 were significantly associated with cancer risk. For -160 C>A polymorphism, -160A allele carriers (CA and CA+AA) had an increased risk of cancer compared with the homozygotes (CC), and the similar result was discovered for the -160A allele in the overall analyses. In the subgroup analyses, obvious elevated risk was found with -160A allele carriers (AA, CA, CA+AA and A allele) for prostate cancer, while a decreased colorectal cancer risk was shown with the AA genotype. For the -347 G>GA polymorphism, the GAGA genotype was associated with increased cancer risk in the overall analysis with homozygous and recessive models. In addition, results of subgroup analysis indicated that the elevated risks were observed in colorectal cancer and Asian descendants. For +54 C>T polymorphism, a decreased risk of cancer was found in heterozygous, dominant and allele models. Moreover, +54T allele carriers (CT, CT+TT genotype and T allele) showed a potential protective factor in gastric cancer and Asian descendants.

Genetic variations in the Hippo signaling pathway and breast cancer risk in African American women in the AMBER Consortium

“…Given the well established role of somatic changes in CDH1 in cancer invasion and metastasis, a number of studies have investigated the associations of CDH1 germline variants with risk of various human cancers. A meta-analysis concluded that one SNP in the promoter region, rs16260 (-160 C>A), was associated with increased risk of all cancers, but not with breast cancer in stratified analyses by cancer type (49). In our AA population, we did not find any association of rs16260 with breast cancer risk.…”

Association between the CDH1-472delA and -160C>A polymorphisms and diffuse and intestinal gastric cancer in a Mexican population

“…This has also been observed in several other populations, as reported in previous meta-analyses (Chen et al, 2011, Cui et al, 2011Wang et al, 2011;Li et al, 2012;Deng et al, 2014;Jiang et al, 2015) including several studies and a large number of samples. However, the mutated genotype A/A of the -160C>A SNP was associated with increased DGC risk in a Mexican population (N = 39 diffuse GC) (20.5%, OR = 6.5, 95%CI = 2.1-19.6) (Medina-Franco et al, 2007).…”

Estrogen Receptor 1 (ESR1) genetic variations in cancer risk: A systematic review and meta-analysis

“…Hardy-Weinberg equilibrium (HWE) was used to evaluate every eligible study by using the goodness-of-fit 2 test as previous study described [12]. ORs with the corresponding 95% CIs were used to estimate the strength of association between ESR1 rs1801132 (C > G), rs2077647 (A > G) and cancer risk.…”